The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Open accessAbstract
Cancer-associated IDH mutations are characterized by neomorphic enzyme activity and resultant 2-hydroxyglutarate (2HG) production. Mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specific hypermethylation signature. Furthermore, expression of 2HG-producing IDH alleles in cells induced global DNA hypermethylation. In the AML cohort, IDH1/2 mutations were mutually exclusive with mutations in the α-ketoglutarate-dependent enzyme TET2, and TET2 loss-of-function mutations were associated with similar epigenetic defects as IDH1/2 mutants. Consistent with these genetic and epigenetic data, expression of IDH mutants impaired TET2 catalytic function in cells. Finally, either expression of mutant IDH1/2 or Tet2 depletion impaired hematopoietic differentiation and increased stem/progenitor cell marker expression, suggesting a shared proleukemogenic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [153]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistently, TET2-mutant immature and myeloid cells present with hypermethylation of active enhancers and perturbed TF activity (28, 32, 53).”
From PU.1-Dependent Enhancer Inhibition Separates Tet2 -Deficient Hematopoiesis from Malignant Transformation (2022) · cites this paper as [53]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [4]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Figueroa et al., 2010
In the citing paper
“Mutations in isocitrate dehydrogenase isoform-1 (IDH1) and IDH2 generate the oncometabolite D-2-hydroxyglutarate (D-2HG), which inhibits epigenetic enzymes including histone demethylases and the Ten-eleven translocation (TET) family of 5-methylcytosine hydroxylases.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“These effects contribute to tumor initiation in acute myelogenous leukemia (AML) by resulting in persistent histone and DNA methylation and impaired cellular differentiation (25).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [25]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [117]
In the citing paper
“In addition, TET2 inactivation is sufficient to promote hematopoietic stem cell self-renewal and to block differentiation (Figueroa et al., 2010; Li et al., 2011; Moran-Crusio et al., 2011; Noushmehr et al., 2010; Turcan et al., 2012; Losman et al., 2013).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“In this regard, TET2 and IDH mutations are both found in acute myelogenous leukemia and are mutually exclusive, consistent with the idea that R-2HG produced by mutant IDH provides an alterative means of inactivating TET2 (Figueroa et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“R-2HG, succinate, and fumarate are all capable of inhibiting multiple 2-oxoglutarate-dependent dioxygenases, including the JmjC histone demethylases and TET proteins, when present at sufficiently high concentrations (Figure 6B) (Cervera et al., 2009; Chowdhury et al., 2011; Figueroa et al., 2010; Koivunen et al., 2012; Lu et al., 2012; Smith et al., 2007; Turcan et al., 2012; Xiao et al., 2012; Xu”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Figueroa et al., 2010
In the citing paper
“More recently, we have also learnt how the catalytic activity of EZH2 can be compromised by so called 'oncohistones' 100 (Figure 3).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“Around 30% of all paediatric glioblastomas contain mutations in histone genes resulting in H3K27M, H3K27I and H3G34V/R substitutions (reviewed in REF. 100 ).”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [100]
In the citing paper
“in a large acute myelogenous leukaemia (AML) cohort, TET2 was found to be mutually exclusive with gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 (REF.65).”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [65]
In the citing paper
“Heterozygous, inactivating ten-eleven translocation 2 (TET2) mutations and neomorphic isocitrate dehydrogenase (IDH) mutations are recurrent and mutually exclusive in acute myeloid leukaemia genomes.”
From Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia (2018) · cites this paper as [5]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [172]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“IDH mutations in AML are mutually exclusive with inactivating mutations in TET2 methylcytosine hydroxylases, further implicating mutant IDH as a bona fide driver of epigenetic remodeling (Figueroa et al., 2010).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Figueroa et al., 2010
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“Mutant IDH2 [Arg140→Gln140 (R140Q)], which promotes α-KG depletion/2-HG production, promotes DNA hypermethylation in hematopoietic cells and can inhibit myeloid differentiation when overexpressed in bone marrow stem cells (79).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [79]
In the citing paper
“multiple groups have found that IDH mutant expression and 2HG elevation can inhibit the TET family of enzymes that hydroxylate 5’-methylcytosine (Figueroa et al., 2010; Turcan et al., 2012; Xu et al., 2011)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“TET2 mutant AML samples displayed an overlapping DNA hypermethylation signature with samples having IDH1 or IDH2 mutations”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“neomorphic mutations of IDH1 or IDH2 and TET2 loss-of-function mutations were found to be mutually exclusive in a large AML cohort”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“In both cell types, the overexpression of IDH mutants blocked acquisition of mature myeloid markers while increasing the expression of stem cell markers (Figueroa et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“shRNA knockdown of TET2 recapitulated the effect of IDH mutant overexpression on blocking hematopoietic cell differentiation (Figueroa et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“mutations in IDH1/2 and in the 5-methylcytosine hydroxylase TET2 occur frequently in acute myelogenous leukemia”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“primary IDH1- or IDH2-mutant tumors showed evidence of extensively altered histone and DNA methylation in vivo”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“the mutations were found to be mutually exclusive”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“high concentrations of 2-HG inhibited the function of α-ketoglutarate-dependent histone demethylases and 5-methylcytosine hydroxylases in vitro”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Figueroa et al., 2010
In the citing paper
“metabolomic profiling of mIDH1/2 gliomas revealed significant alterations in cellular metabolism, an effect recapitulated with the exogenous addition of D-2-HG134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
In the citing paper
“This metabolic rewiring resulted in a decrease in a common dipeptide found in the brain N-acetyl-aspartyl-glutamate (NAAG), and NAAG levels were found to be significantly lower in IDH-mutant human glioma tissue134.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationIto, S., D’Alessio, A. C., Taranova, O., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,628
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Histone demethylation by a family of JmjC domain-containing proteins
Tsukada, Y.-I., Fang, J., Erdjument‐Bromage, H., Warren, M., Borchers, C. H., Tempst, P., & Zhang, Y. (2005) · Nature · doi:10.1038/nature04433 · Cited by 2,244
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,005
Metabolic Modulation of Epigenetics in Gliomas
Venneti, S., & Thompson, C. B. (2013) · Brain Pathology · doi:10.1111/bpa.12022 · Cited by 56
Self-citationA nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis
Shen, N., Yan, F., Pang, J., Wu, L., Al‐Kali, A., Litzow, M. R., & Liu, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2131 · Cited by 55
Ma, S., Jiang, B., Deng, W., Gu, Z.-K., Wu, F.-Z., Li, T., Xia, Y., Yang, H., Ye, D., Xiong, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3330 · Cited by 57
Jin, J., Hu, C., Yu, M., Chen, F., Ye, L., Yin, X., Zhuang, Z., & Tong, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100206 · Cited by 56
A mechanistic overview of TET-mediated 5-methylcytosine oxidation
Ponnaluri, V. K. C., Maciejewski, J. P., & Mukherji, M. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.05.077 · Cited by 55
Weichenhan, D., & Plass, C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt348 · Cited by 58
Sinha, S., Thomas, D., Yu, L. C., Gentles, A. J., Jung, N., Corces, M. R., Chan, S. M., Reinisch, A., Feinberg, A. P., Dill, D. L., et al. (2014) · Blood · doi:10.1182/blood-2014-03-566018 · Cited by 60
Targeting Metabolic Changes in Cancer: Novel Therapeutic Approaches
Bobrovnikova-Marjon, E. V., & Hurov, J. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112344 · Cited by 56
TET3 Inhibits Type I IFN Production Independent of DNA Demethylation
Xue, S., Liu, C., Sun, X., Li, W., Zhang, C., Zhou, X., Lu, Y., Xiao, J., Li, C., Xu, X., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.068 · Cited by 55
Yan, F., Shen, N., Pang, J. X., Zhao, N., Zhang, Y. W., Bode, A. M., Al‐Kali, A., Litzow, M. R., Li, B., & Liu, S. (2017) · Leukemia · doi:10.1038/leu.2017.307 · Cited by 57
The clinical use of IDH1 and IDH2 mutations in gliomas
Pïcca, A., Berzero, G., Stefano, A. L. D., & Sanson, M. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1548935 · Cited by 55
TET2: A cornerstone in normal and malignant hematopoiesis
Kunimoto, H., & Nakajima, H. (2020) · Cancer Science · doi:10.1111/cas.14688 · Cited by 56
Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management
Chan, T. A.-T., Ho, A. S., & Turcan, Ş. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s34680 · Cited by 54
Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
Fleischmann, M., Schnetzke, U., Hochhaus, A., & Scholl, S. (2021) · Cancers · doi:10.3390/cancers13225722 · Cited by 59
Fathi, A. T., Kim, H. T., Soiffer, R. J., Levis, M. J., Li, S., Kim, A. S., DeFilipp, Z. M., El-Jawahri, A. R., McAfee, S. L., Brunner, A. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0182 · Cited by 55
Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
Fruchtman, H., Avigan, Z. M., Waksal, J. A., Brennan, N., & Mascarenhas, J. O. (2024) · Leukemia · doi:10.1038/s41375-024-02246-2 · Cited by 59
Some promising medicinal plants used in Alzheimer’s disease: an ethnopharmacological perspective
Bordoloi, S., Pathak, K., Devi, M., Saikia, R., Das, J., Kashyap, V. H., Das, D., Ahmad, M. Z., & Abdel‐Wahab, B. A. (2024) · Discover Applied Sciences · doi:10.1007/s42452-024-05811-7 · Cited by 54
Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer
Lanzetti, L. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01402-6 · Cited by 57
Ravandi, F., Patel, K. P., Luthra, R., Faderl, S. H., Konopleva, M. Y., Kadia, T. M., Brandt, M., Pierce, S. A., Kornblau, S. M., Andreeff, M., et al. (2011) · Cancer · doi:10.1002/cncr.26580 · Cited by 55
Ye, C., & Li, L. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.27144 · Cited by 56
Molecular Markers in Low-Grade Glioma—Toward Tumor Reclassification
Olar, A., & Sulman, E. P. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2015.02.006 · Cited by 56
Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma
Grassian, A. R., Pagliarini, R. A., & Chiang, D. Y. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000050 · Cited by 54
The good, the bad and the ugly: Epigenetic mechanisms in glioblastoma
Carén, H., Pollard, S. M., & Beck, S. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.06.007 · Cited by 55
Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers
Ichimura, K., Narita, Y., & Hawkins, C. E. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1439-7 · Cited by 56
Metabolic interactions with cancer epigenetics
Gao, X., Reid, M. A., Kong, M., & Locasale, J. W. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.09.001 · Cited by 55
Zhang, J., & Huang, K. (2017) · BMC Genomics · doi:10.1186/s12864-016-3259-0 · Cited by 55
The degree of mitochondrial DNA methylation in tumor models of glioblastoma and osteosarcoma
Sun, X., Vaghjiani, V., Jayasekara, W. S. N., Cain, J. E., & John, J. C. S. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0590-0 · Cited by 54
Trisomy 8 in acute myeloid leukemia
Hemsing, A. L., Hovland, R., Tsykunova, G., & Reikvam, H. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1657400 · Cited by 56
Kattih, B., Shirvani, A., Klement, P., Garrido, A. M., Gabdoulline, R. R., Liebich, A., Brandes, M., Chaturvedi, A., Seeger, T., Thol, F. R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01043-x · Cited by 57
Genetic Events That Shape the Cancer Epigenome
Ryan, R. J. H., & Bernstein, B. (2012) · Science · doi:10.1126/science.1223730 · Cited by 55
Exercise and the Skeletal Muscle EpigenomePreprint
McGee, S. L., & Walder, K. R. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029876 · Cited by 56
Cierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
Metabolism-driven chromatin dynamics: Molecular principles and technological advances
Sahu, V., & Lü, C. (2025) · Molecular Cell · doi:10.1016/j.molcel.2024.12.012 · Cited by 56
Inherited predisposition to myeloproliferative neoplasms
Jones, A. V., & Cross, N. C. P. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713489144 · Cited by 58
Metabolic Profiling, a Noninvasive Approach for the Detection of Experimental Colorectal Neoplasia
Montrose, D. C., Zhou, X. K., Kopelovich, L., Yantiss, R. K., Karoly, E. D., Subbaramaiah, K., & Dannenberg, A. J. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0160 · Cited by 53
Wang, J., Yang, J., Li, D., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188454 · Cited by 53
Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical ImplicationsPreprint
Yegnasubramanian, S., Marzo, A. M. D., & Nelson, W. G. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030445 · Cited by 53
Engineering subtle targeted mutations into the mouse genome
Menke, D. B. (2013) · genesis · doi:10.1002/dvg.22422 · Cited by 53
Masalmeh, R. H. A., Taglini, F., Rubio-Ramon, C., Musialik, K. I., Higham, J., Davidson‐Smith, H., Kafetzopoulos, I., Pawlicka, K. P., Finan, H., Clark, R. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20716-w · Cited by 54
Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma
Chai, P., Jia, R., Li, Y., Zhou, C., Gu, X., Yang, L., Shi, H., Tian, H., Lin, H., Yu, J., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101030 · Cited by 56
Self-citationAn Overview of Targeted Therapies in Acute Myeloid Leukemia
Turkalj, S., Radtke, F. A., & Vyas, P. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000914 · Cited by 54
Wakita, S., Yamaguchi, H., Ueki, T., Usuki, K., Kurosawa, S., Kobayashi, Y., Kawata, E., Tajika, K., Gomi, S., Koizumi, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.288 · Cited by 52
Differential Effects on ARF Stability by Normal versus Oncogenic Levels of c-Myc Expression
Chen, D., Kon, N., Zhong, J., Zhang, P., Yu, L., & Gu, W. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.006 · Cited by 55
Antagonistic functional duality of cancer genes
Stepanenko, A. A., Vassetzky, Y. S., & KAVSAN, V. M. (2013) · Gene · doi:10.1016/j.gene.2013.07.047 · Cited by 54
Alterations of 5-Hydroxymethylcytosine in Human Cancers
Mariani, C. J., Madžo, J., Moen, E. L., Yesilkanal, A. E., & Godley, L. A. (2013) · Cancers · doi:10.3390/cancers5030786 · Cited by 53
Self-citationYamaguchi, S., Iwanaga, E., Tokunaga, K., Nanri, T., Shimomura, T., Suzushima, H., Mitsuya, H., & Asou, N. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12271 · Cited by 52
Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia
Gallipoli, P., Giotopoulos, G., & Huntly, B. J. P. (2015) · Therapeutic Advances in Hematology · doi:10.1177/2040620715577614 · Cited by 53
Molecular subtyping of prostate cancer
Kaffenberger, S. D., & Barbieri, C. E. (2016) · Current Opinion in Urology · doi:10.1097/mou.0000000000000285 · Cited by 52
Ichimura, N., Shinjo, K., An, B., Shimizu, Y., Yamao, K., Ohka, F., Katsushima, K., Hatanaka, A., Tojo, M., Yamamoto, E., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0306 · Cited by 55
Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis
Pronier, E., Bowman, R. L., Ahn, J., Glass, J. L., Kandoth, C., Merlinsky, T. R., Whitfield, J. T., Durham, B. H., Gruet, A., Somasundara, A. V. H., et al. (2018) · Blood · doi:10.1182/blood-2018-03-837468 · Cited by 52
Self-citationGlutamine metabolism in cancer therapy
Nguyen, T.-L., & Durán, R. V. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.08 · Cited by 56
Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy
Bergaggio, E., & Piva, R. (2019) · Cancers · doi:10.3390/cancers11040563 · Cited by 52
Das, A. B., Kakadia, P. M., Wojcik, D. P., Pemberton, L. C., Browett, P., Bohlander, S. K., & Vissers, M. C. M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0242-4 · Cited by 54
The role of DNA-demethylating agents in cancer therapy
Mehdipour, P., Murphy, T., & Carvalho, D. D. D. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107416 · Cited by 55
Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation
Boy, M., Bisio, V., Zhao, L., Guidez, F., Schell, B., Lereclus, E., Henry, G., Villemonteix, J., Rodrigues‐Lima, F., Gagne, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36193-w · Cited by 51
Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer
Viel, S., Vivier, É., Walzer, T., & Marçais, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01098-w · Cited by 53
Role of somatic cancer mutations in human protein lysine methyltransferases
Kudithipudi, S., & Jeltsch, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.08.002 · Cited by 55
Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group
Nomdedeu, J. F., Hoyos, M., Carricondo, M., Esteve, J., Bussaglia, E., Estivill, C., Ribera, J., Duarte, R. F., Salamero, O., Gallardo, D., et al. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.03.019 · Cited by 51
Comparative analysis of affinity-based 5-hydroxymethylation enrichment techniques
Thomson, J. P., Hunter, J. M., Nestor, C. E., Dunican, D. S., Terranova, R., Moggs, J. G., & Meehan, R. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1080 · Cited by 51
Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations
Lin, T., Nagata, Y., Kao, H., Sanada, M., Okuno, Y., Huang, C. F., Liang, D.-C., Kuo, M. ‐., Lai, C., Lee, E. H., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.091249 · Cited by 51
Brennan, C. W. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0198-7 · Cited by 51
Myeloproliferative neoplasms: Current molecular biology and genetics
Saeidi, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.004 · Cited by 53
Roles of IDH1/2 and TET2 mutations in myeloid disorders
Inoue, S., Lemonnier, F., & Mak, T. W. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1973-7 · Cited by 52
Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia
Wang, M., Yang, C., Zhang, L., & Schaar, D. G. (2017) · Stem Cells International · doi:10.1155/2017/6962379 · Cited by 52
Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy
Castelli, G., Pelosi, E., & Testa, U. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s145971 · Cited by 51
Lin, J., Lu, W., Caravella, J. A., Campbell, A. M., Diebold, R. B., Ericsson, A. M., Fritzen, E. L., Gustafson, G. R., Lancia, D. R., Shelekhin, T. E., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00362 · Cited by 51
TET enzymatic oxidation of 5-methylcytosine, 5-hydroxymethylcytosine and 5-formylcytosine
Cadet, J., & Wagner, J. R. (2013) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2013.09.001 · Cited by 53
Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers
Bledea, R., Vasudevaraja, V., Patel, S. V., Stafford, J. M., Serrano, J., Esposito, G., Tredwin, L. M., Goodman, N. E., Kloetgen, A., Golfinos, J. G., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53262-7 · Cited by 52
Egan, G., Khan, D. H., Lee, J. B., Mirali, S., Zhang, L., & Schimmer, A. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1227 · Cited by 52
Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma
Jiang, H., Greathouse, R. L., Tiche, S. J., Zhao, M., He, B., Li, Y., Li, A. M., Forgo, B. L., Yip, M., Li, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1029 · Cited by 50
Self-citationConcise Review: Leukemia Stem Cells in Personalized Medicine
Guzmán, M. L., & Allan, J. N. (2013) · Stem Cells · doi:10.1002/stem.1597 · Cited by 52
Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights
Ng, K., Kim, R., Kesari, S., Carter, B. S., & Chen, C. C. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0714-2 · Cited by 50
Chen, R., Ravindra, V. M., Cohen, A. L., Jensen, R. L., Salzman, K. L., Prescot, A. P., & Colman, H. (2015) · Neurosurgical FOCUS · doi:10.3171/2015.1.focus14745 · Cited by 50
The role of chromatin modifiers in normal and malignant hematopoiesis
Napierala, J. S., & Dent, S. (2013) · Blood · doi:10.1182/blood-2012-10-451237 · Cited by 55
The biology and clinical impact of genetic lesions in myeloid malignancies
Lindsley, R. C., & Ebert, B. L. (2013) · Blood · doi:10.1182/blood-2013-06-460295 · Cited by 50
Role of DNA Methylation in the Pathogenesis and Treatment of Myelodysplastic Syndromes
Khan, H., Vale, C., Bhagat, T. D., & Verma, A. K. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.01.001 · Cited by 50
Molecular oncogenesis of chondrosarcoma: impact for targeted treatment
Speetjens, F. M., de Jong, Y., Gelderblom, H. A. J., & Bovée, J. V. M. G. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000300 · Cited by 50
High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients
Giansanti, M., Karimi, T., Faraoni, I., & Graziani, G. (2021) · Cancers · doi:10.3390/cancers13061428 · Cited by 50
Noreen, F., Küng, T., Tornillo, L., Parker, H. R., Silva, M. G., Weis, S., Marra, G., Rad, R., Truninger, K., & Schär, P. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0791-1 · Cited by 49
Johnston, K., Pachnis, P., Tasdogan, A., Faubert, B., Zacharias, L. G., Vu, H., Rodgers-Augustyniak, L. A., Johnson, A., Huang, F., Ricciardo, S., et al. (2021) · Med · doi:10.1016/j.medj.2021.01.002 · Cited by 52
RNA modifications in hematopoietic malignancies: a new research frontier
Qing, Y., Su, R. J., & Chen, J. (2021) · Blood · doi:10.1182/blood.2019004263 · Cited by 51
Oxidative stress and metabolism meet epigenetic modulation in physical exercise
García‐Giménez, J. L., Cánovas‐Cervera, I., & Pallardó, F. V. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.008 · Cited by 50
Advancements and Challenges in the Treatment of AML
Abaza, Y., McMahon, C. M., & Garcia, J. S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438662 · Cited by 49
Hypoxia and Metabolism in Cancer
Bensaad, K., & Harris, A. L. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_1 · Cited by 49
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies
Mascarenhas, J. O., Roper, N., Chaurasia, P., & Hoffman, R. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0050-6 · Cited by 51
Gatekeepers of chromatin: Small metabolites elicit big changes in gene expression
Kaochar, S., & Tu, B. P. (2012) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2012.07.008 · Cited by 49
Ofran, Y., & Rowe, J. M. (2012) · British Journal of Haematology · doi:10.1111/bjh.12135 · Cited by 51
Liu, X., Zhang, G., Yi, Y., Xiao, L., Pei, M.-F., Liu, S., Luo, Y., Zhong, H., Xu, Y., Zheng, W., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.778408 · Cited by 50
Walker, O. S., Elsässer, S. J., Mahesh, M., Bachman, M., Balasubramanian, S., & Chin, J. W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b07627 · Cited by 49
miR-199b, a novel tumor suppressor miRNA in acute myeloid leukemia with prognostic implications
Favreau, A. J., McGlauflin, R., Duarte, C. W., & Sathyanarayana, P. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-016-0033-6 · Cited by 49
Epigenetics: A primer for clinicians
Paluch, B. E., Naqash, A. R., Brumberger, Z. L., Nemeth, M. J., & Griffiths, E. A. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.02.002 · Cited by 50
Fujii, S., Shinjo, K., Matsumoto, S., Harada, T., Nojima, S., Sato, S., Usami, Y., Toyosawa, S., Morii, E., Kondo, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13147 · Cited by 49
A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit
Kopinja, J. E., Sevilla, R. S., Levitan, D. J., Dai, D. L., Vanko, A., Spooner, E., Ware, C., Forget, R., Hu, K., Kral, A. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14065-w · Cited by 49
Oncometabolites in cancer aggressiveness and tumour repopulation
Dando, I., Pozza, E. D., Ambrosini, G., Torrens‐Mas, M., Butera, G., Mullappilly, N., Pacchiana, R., Palmieri, M., & Donadelli, M. (2019) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12513 · Cited by 49
Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis
Yauch, R. L., & Settleman, J. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.01.003 · Cited by 48
Epigenetics in normal and malignant hematopoiesis: An overview and update 2017
Goyama, S., & Kitamura, T. (2017) · Cancer Science · doi:10.1111/cas.13168 · Cited by 53
Gunn, K., Myllykoski, M., Cao, J. Z., Ahmed, M., Huang, B., Rouaisnel, B., Diplas, B. H., Levitt, M. M., Looper, R., Doench, J. G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0825 · Cited by 57
Self-citationDinardo, C. D., Verma, D., Baran, N., Bhagat, T. D., Skwarska, A., Lodi, A., Saxena, K., Cai, T., Su, X., Guerra, V. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00811-3 · Cited by 48
Ho, P. A., Kopecky, K. J., Alonzo, T. A., Gerbing, R. B., Miller, K. L., Kuhn, J., Zeng, R., Ries, R. E., Raimondi, S. C., Hirsch, B. A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348888 · Cited by 48
Genetics of the myeloproliferative neoplasms
Abdel-Wahab, O. I. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328343998e · Cited by 48
Self-citation
Metadata
- Authors
- Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., Tallman, M. S., Sun, Z., Wolniak, K., Peeters, J. K., Liu, W., Choe, S. E., Fantin, V. R., Paietta, E., Löwenberg, B., Licht, J. D., Godley, L. A., Delwel, R., Valk, P. J. M., Thompson, C. B., Levine, R. L., & Melnick, A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Abramson Cancer Center (US)
- Weill Cornell Medicine (US)
- University of Chicago (US)
- Moffitt Cancer Center (US)
- Harvard University (US)
- Northwestern University (US)
- Erasmus MC (NL)
- Agios Pharmaceuticals (United States) (US)
- Montefiore Medical Center (US)
- Corresponding author
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- ORCID
- Abdel-Wahab, Omar
- Ward, Patrick S.
- Patel, Jay
- Shih, Alan
- Li, Yushan
- Bhagwat, Neha
- Vasanthakumar, Aparna
- Fernandez, Hugo F.
- Tallman, Martin S.
- Sun, Zhuoxin
- Wolniak, Kristy
- Liu, Wei
- Choe, Sung E.
- Fantin, Valeria R.
- Paietta, Elisabeth
- Löwenberg, Bob
- Licht, Jonathan D.
- Godley, Lucy A.
- Delwel, Ruud
- Valk, Peter J.M.
- Thompson, Craig B.
- Levine, Ross L.
- Melnick, Ari
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 18
- Issue
- 6
- Pages
- 553-567
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC4105845
- OpenAlex
- W2078972833
- Cited by
- 2,766
- References
- 35
- Citations by year
- 2026: 92 · 2025: 114 · 2024: 156 · 2023: 158 · 2022: 155 · 2021: 213 · 2020: 183 · 2019: 165 · 2018: 178 · 2017: 196 · 2016: 186 · 2015: 193 · 2014: 217 · 2013: 214 · 2012: 191
- FWCI
- 111.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- Agios Pharmaceuticals
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL082950)
- National Cancer Institute (CA114737, R01CA105463, U54CA143798, U24CA114737, R01CA173636, U10CA021115, CA 21115)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, IDH2 mutation, acute myeloid leukemia, DNA hypermethylation, 2-hydroxyglutarate, TET2, hematopoietic differentiation, epigenetic dysregulation, stem/progenitor cells
- MeSH terms
- MDS1 and EVI1 Complex Locus Protein, Cell Differentiation, DNA-Binding Proteins, Humans, Hydroxylation, Isocitrate Dehydrogenase, Mutation, Phenotype, Proto-Oncogene Proteins, Proto-Oncogenes, Transcription Factors, Leukemia, Myeloid, Acute, DNA Methylation, Myeloid Cells, 5-Methylcytosine, Dioxygenases, GATA1 Transcription Factor, Gene Regulatory Networks
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
